SCHEMBL4388048

SCHEMBL4388048

NC(=O)c1ccccc1CNC1CCC(=O)NC1=O

nearest known ligand 0.54

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 20/20 0.54
DDB1 Q16531 11/20 0.49
IKZF3 Q9UKT9 1/20 0.44
BRD4 O60885 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4392066 1.00 CRBN (0.54) CRBNDDB1IKZF3BRD4
SCHEMBL4388045 1.00 CRBN (0.54) CRBNDDB1IKZF3BRD4
SCHEMBL4400590 0.89 CRBN (0.56) CRBNDDB1IKZF3BRD4
SCHEMBL4400598 0.89 CRBN (0.56) CRBNDDB1IKZF3BRD4
SCHEMBL4399379 0.89 CRBN (0.56) CRBNDDB1IKZF3
SCHEMBL4388040 0.89 CRBN (0.56) CRBNDDB1IKZF3
SCHEMBL4388041 0.89 CRBN (0.56) CRBNDDB1IKZF3
SCHEMBL6692888 0.88 CRBN (0.51) CRBNDDB1IKZF3BRD4
SCHEMBL4400886 0.85 CRBN (0.56) CRBNDDB1
SCHEMBL4400882 0.85 CRBN (0.56) CRBNDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1252144-B1 SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS GRUENENTHAL GMBH (DE) 2009-12-09 EP claimed
US-20040048859-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GRUENENTHAL GMBH (DE) 2004-03-11 US claimed
US-6656937-B2 Immunology moderators; interleukin antagonist; anticancer agents GRUENENTHAL, GMBH (DE) 2003-12-02 US claimed
US-20030064987-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GRUENENTHAL GMBH 2003-04-03 US claimed
US-20040048859-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GRUENENTHAL GMBH (DE) 2004-03-11 US disclosed
US-6656937-B2 Immunology moderators; interleukin antagonist; anticancer agents GRUENENTHAL, GMBH (DE) 2003-12-02 US disclosed
US-20030064987-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GRUENENTHAL GMBH 2003-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048859-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GCDH, IL4I1, IL2 CRBN 949/4885DDB1 2435/4885IKZF3 1978/4885
US-20030064987-A1 Substituted glutarimides and their use as inhibitors of IL-12 production GCDH, IL4I1, IL2 CRBN 949/4885DDB1 2435/4885IKZF3 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.